Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Residual OXPHOS is required to drive primary and metastatic lung tumours in an orthotopic breast cancer model

P. Herst, G. Carson, D. Lewthwaite, D. Eccles, A. Schmidt, A. Wilson, C. Grasso, D. O'Sullivan, J. Neuzil, M. McConnell, M. Berridge

. 2024 ; 14 (-) : 1362786. [pub] 20240501

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012868

BACKGROUND: Fast adaptation of glycolytic and mitochondrial energy pathways to changes in the tumour microenvironment is a hallmark of cancer. Purely glycolytic ρ0 tumour cells do not form primary tumours unless they acquire healthy mitochondria from their micro-environment. Here we explored the effects of severely compromised respiration on the metastatic capability of 4T1 mouse breast cancer cells. METHODS: 4T1 cell lines with different levels of respiratory capacity were generated; the Seahorse extracellular flux analyser was used to evaluate oxygen consumption rates, fluorescent confocal microscopy to assess the number of SYBR gold-stained mitochondrial DNA nucleoids, and the presence of the ATP5B protein in the cytoplasm and fluorescent in situ nuclear hybridization was used to establish ploidy. MinION nanopore RNA sequence analysis was used to compare mitochondrial DNA transcription between cell lines. Orthotopic injection was used to determine the ability of cells to metastasize to the lungs of female Balb/c mice. RESULTS: OXPHOS-deficient ATP5B-KO3.1 cells did not generate primary tumours. Severely OXPHOS compromised ρ0D5 cells generated both primary tumours and lung metastases. Cells generated from lung metastasis of both OXPHOS-competent and OXPHOS-compromised cells formed primary tumours but no metastases when re-injected into mice. OXPHOS-compromised cells significantly increased their mtDNA content, but this did not result in increased OXPHOS capacity, which was not due to decreased mtDNA transcription. Gene set enrichment analysis suggests that certain cells derived from lung metastases downregulate their epithelial-to-mesenchymal related pathways. CONCLUSION: In summary, OXPHOS is required for tumorigenesis in this orthotopic mouse breast cancer model but even very low levels of OXPHOS are sufficient to generate both primary tumours and lung metastases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012868
003      
CZ-PrNML
005      
20240726151432.0
007      
ta
008      
240723e20240501sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2024.1362786 $2 doi
035    __
$a (PubMed)38751813
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Herst, Patries $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand $u Department of Radiation Therapy, University of Otago, Wellington, New Zealand
245    10
$a Residual OXPHOS is required to drive primary and metastatic lung tumours in an orthotopic breast cancer model / $c P. Herst, G. Carson, D. Lewthwaite, D. Eccles, A. Schmidt, A. Wilson, C. Grasso, D. O'Sullivan, J. Neuzil, M. McConnell, M. Berridge
520    9_
$a BACKGROUND: Fast adaptation of glycolytic and mitochondrial energy pathways to changes in the tumour microenvironment is a hallmark of cancer. Purely glycolytic ρ0 tumour cells do not form primary tumours unless they acquire healthy mitochondria from their micro-environment. Here we explored the effects of severely compromised respiration on the metastatic capability of 4T1 mouse breast cancer cells. METHODS: 4T1 cell lines with different levels of respiratory capacity were generated; the Seahorse extracellular flux analyser was used to evaluate oxygen consumption rates, fluorescent confocal microscopy to assess the number of SYBR gold-stained mitochondrial DNA nucleoids, and the presence of the ATP5B protein in the cytoplasm and fluorescent in situ nuclear hybridization was used to establish ploidy. MinION nanopore RNA sequence analysis was used to compare mitochondrial DNA transcription between cell lines. Orthotopic injection was used to determine the ability of cells to metastasize to the lungs of female Balb/c mice. RESULTS: OXPHOS-deficient ATP5B-KO3.1 cells did not generate primary tumours. Severely OXPHOS compromised ρ0D5 cells generated both primary tumours and lung metastases. Cells generated from lung metastasis of both OXPHOS-competent and OXPHOS-compromised cells formed primary tumours but no metastases when re-injected into mice. OXPHOS-compromised cells significantly increased their mtDNA content, but this did not result in increased OXPHOS capacity, which was not due to decreased mtDNA transcription. Gene set enrichment analysis suggests that certain cells derived from lung metastases downregulate their epithelial-to-mesenchymal related pathways. CONCLUSION: In summary, OXPHOS is required for tumorigenesis in this orthotopic mouse breast cancer model but even very low levels of OXPHOS are sufficient to generate both primary tumours and lung metastases.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Carson, Georgia $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
700    1_
$a Lewthwaite, Danielle $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand $u School of Biological Sciences , Victoria University of Wellington, Wellington, New Zealand
700    1_
$a Eccles, David $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
700    1_
$a Schmidt, Alfonso $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
700    1_
$a Wilson, Andrew $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
700    1_
$a Grasso, Carole $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
700    1_
$a O'Sullivan, David $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
700    1_
$a Neuzil, Jiri $u Institute of Biotechnology of the Czech Academy of Sciences, Prague-West, Czechia $u School of Pharmacy and Medical Science, Griffith University, Southport, QLD, Australia
700    1_
$a McConnell, Melanie $u School of Biological Sciences , Victoria University of Wellington, Wellington, New Zealand
700    1_
$a Berridge, Michael $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 14 (20240501), s. 1362786
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38751813 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151425 $b ABA008
999    __
$a ok $b bmc $g 2125502 $s 1224731
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 14 $c - $d 1362786 $e 20240501 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...